Disclosures: Max Goldman: Eli Lilly: Stock - publicly traded company, Novo Nordisk: Stock - publicly traded company, Eli Lilly: Stock - publicly traded company, Madrigal: Stock - publicly traded company, Janet Chu: Gilead Sciences, Inc.: Grant/Research Support, Nghiem Ha: Nothing to Disclose, Bilal Hameed: Gilead: Grant/Research Support, Intercept: Grant/Research Support, Pliant: Grant/Research Support, Novo Nordisk: Grant/Research Support, Madrigal: Grant/Research Support, Salix: Grant/Research Support, Mallinckrodt: Advisor, Pleiogenix: Advisor, CLDF: Advisor, Gilead: Consultant, Pioneering Medicine VII Inc: Consultant, Surrozen: Consultant, Pleiogenix: Stock privately held company, Scholars In Medicine: Speaking and Teaching, Mandana Khalili: gilead sciences: Grant/Research Support, GSK pharmaceuticals: Consultant, Intercept pharmaceuticals: Grant/Research Support, Gilead Sciences Inc: Consultant, Rena Fox: Nothing to Disclose 785 PERFORMANCE OF NONINVASIVE TESTS IN IDENTIFYING APPROPRIATE PATIENTS FOR RESMETIROM TREATMENT: REAL WORLD DATA FROM FOUR TERTIARY CARE CENTERS Eda Kaya 1 Rida Nadeem 2 Ayana Jain 2 Reyana Shah 2 Sahasraara Hemant 2 Sohil Kahlon 2 Chloe Nguyen 2 Manal Chughtai 2 Jan-Peter Sowa 1 Ali Canbay 1 Raj Vuppalanchi 3 Yusuf Yilmaz 4 Naim Alkhouri 2 , 1 Knappschaftskrankenhaus Bochum, 2 Arizona Liver Health, 3 Indiana University, 4 Recep Tayyip Erdogan University Background: Resmetirom was recently approved as the first medication for patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages F2-F3
Recent advances in research on the gut-lung axis have provided novel insights into its pathophysiology and revealed potential therapeutic targets
Nature Cell Biology, 8 (2), 163169
This disruption is responsible for the increase in microvascular permeability and local post-infarction edematous state [121]
